Myrtelle
Wakefield
About Myrtelle
Myrtelle is a gene therapy company that offers clinical trials for the treatment of rare monogenetic disorders. It helps in addressing an array of diseases with white matter involvement that includes demyelinating diseases and ASPA-associated disorders with rare CNS diseases. It also helps healthcare professionals to develop and deliver novel treatments for devastating disorders of the central nervous system and transform the treatment of neurological diseases that improve the quality of life and longevity. The company's mission is to develop and deliver novel treatments for devastating disorders of the central nervous system, beginning with its lead program, gene therapy treatment for Canavan disease. It was founded in 2020 and is headquartered in Wakefield, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $57.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: myrtellegtx.com
- Phone: 781-621-2381
Industries & Categories
Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/myrtelle-55844 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.